EFFICACY AND SAFETY OF GLYCOPROTEIN IIB/IIIA BLOCKER MONOFRAM IN CORONARY STENTING IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
https://doi.org/10.20996/1819-6446-2011-7-4-452-456
Abstract
Aim. To study of efficacy and safety of glycoprotein IIb/IIIa blocker monafram in acute ST-segment elevation myocardial infarction (STEMI) patients, underwent coronary stenting. Material and methods. 220 STEMI patients were included in the trial; they were split into two groups. 109 patients of the first group were underwent coronary stenting with i/v monafram therapy. Coronary stenting without monafram therapy was performed in 111 patients of the second group. Bare metal stents were used in all patients. Deaths, stent thrombosis, individual intolerance, allergic reactions, bleeding were registered during hospitalization. Results. There were 3 (2.75%) cases of stent thrombosis in monafram group and 4 (3.6%) ones - in the control group. Good tolerance of monafram was observed in all patients. There were no allergic reactions, major and minor bleedings. Reinfarction rate was similar in both groups during 30 days observational period. Conclusions. Monafram therapy is effective and safe in acute STEMI patients underwent coronary stenting.
About the Authors
E. I. Makhiyanova
Kazan State Medical University
Interregional Clinical and Diagnostic Center
Russian Federation
Russian Federation
A. S. Galyavich
Kazan State Medical University
Interregional Clinical and Diagnostic Center
Russian Federation
Russian Federation
References
1. Pearson T.A., Blair S.N., Daniels S.R. et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update; consensus panel guide to comprehensive risk reduction for adult patients without coronary or atherosclerotic vascular diseases. Circulation 2002; 106: 388-91.
2. Wagner C.L., Neblock D.S., Weisman H.F., Coller B.S., Jordan R.E. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88: 907-914.
3. De Jong M.J., Wright S.L. New adjunctive therapy for ischemic syndromes. Crit Care Nurs Clin North Am 1999;11: 355-371.
4. Сoller B.S. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001;86: 427-443.
5. Brown D.L., Fann C.S., Chang C.J. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87: 537-541.
6. The RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96: 1445-53.
7. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2001;356:2037-44.
8. Moliteno D.J., Calff R.H., Ageirre F.V. EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330: 956-61.
9. The CAPTURE Investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-1435.
10. The EPISTENT Investigators. Randomized placebo controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa binding. Lancet 1998; 352: 87-92.
11. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98: 2695-2701.
12. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. New Engl J Med 2001;344:1895-1903.
13. Antoniucci D., Rodriguez A., Hempel A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003;42: 1879-1885.
14. The TARGET investigators. Comparison of two platelet IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344: 1888-94.
15. Mazurov A.V., Pevzner D.V., Vlasik T.N., Ruda M.Ia. Antiplatelet effects of glycoproteins IIb-IIIa antagonist monafram. Ross Fiziol Zh Im I M Sechenova 2004;90(5):586-99. Russian (Мазуров А.В., Певзнер Д.В., Власик Т.Н., Руда М.Я. Антитромбоцитарные эффекты антагониста гликопротеинов IIb/IIIa Монафрама. Российский физиологический журнал им. И.М. Сеченова 2004;90 (5): 586-99).
16. Mazurov A.V., Pevzner D.V., Staroverov I.I. et al. Results of clinical trials of a novel glycoprotein IIb-IIIa antagonist framon in high-risk coronary angioplasty. Kardiologiia 2005;45(5):4-12. Russian (Мазуров А.В., Певзнер Д.В., Староверов И.И. и др. Результаты клинических испытаний нового антагониста гликопротеинов IIb/IIIa монафрама при коронарной ангиопластике высокого риска. Кардиология 2005;5: 4-12).
17. Mazurov A.V., Pevzner D.V., Khaspekova S.G. et al. Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa. Ter Arkh 2001;73(9):66-73. Russian (Мазуров А.В., Певзнер Д.В., Хаспекова С.Г. и др. Ингибирование агрегации тромбоцитов F(ab’)2-фрагментами моноклонального антитела ФраМон (CRC64) против гликопротеидов IIb/IIIа. Исследование in vitro при введении здоровым добровольцам. Тер арх 2001;73: 66-73).
18. Mazurov A.V., Pevzner D.V., Semenov A.V. et al. Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty. Kardiologiia 2002;42(6):8-17. Russian (Мазуров А.В., Певзнер Д.В., Семенов А.В. И др. Фармакодинамика, безопасность и клинические эффекты нового антагониста гликопротеидов IIb/IIIа фрамона при коронарной ангиопластике высокого риска. Кардиология 2002;42: 8-17).
19. Mazurov A.V., Pevzner D.V., Antonova O.A. et al. Safety, inhibition of platelet aggregation and pharmacokinetics of F(ab’)2 fragments of the anti-glycoprotein IIb/IIIа monoclonal antibody FRaMon in high-risk coronary angioplasty. Platelets 2002;13: 465-477.
Review
For citations:
Makhiyanova E.I., Galyavich A.S. EFFICACY AND SAFETY OF GLYCOPROTEIN IIB/IIIA BLOCKER MONOFRAM IN CORONARY STENTING IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. Rational Pharmacotherapy in Cardiology. 2011;7(4):452-456. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-4-452-456
Views:
711
.jpg)
Email this article 